The role of histone deacetylase inhibitors in metastatic breast cancer. (February 2019)

• Record Type: Journal Article
• Authors: Zucchetti, Bruna; Shimada, Andrea Kazumi; Katz, Artur; Curigliano, Giuseppe
• Is Part Of: Breast. Volume 43(2019)
• Page Start: 130
• Page End: 134
• Publication Date: 2019-02
• Subjects: Breast cancer -- Epigenetic -- Histone acetylation; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2018.12.001
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.